EUVIMEDEUVIMED entdecken
Crossref

Thymic Epithelial Hyperplasia and Thymoma in Control rasH2 Transgenic Mice From 26-Week Carcinogenicity Assays

Sasmita Mishra iD, Vimala Vemireddi iD, Marcia E Pereira Bacares iD, Molly H Boyle iD, Mark Mense iD, Alok K Sharma iD

Toxicologic Pathology · 2026-06 · 54 (4) · 297-306

DOI: 10.1177/01926233261429439 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Toxicologic Pathology, online erschienen am 05.04.2026. Verfasst von Sasmita Mishra und 5 weiteren Autor:innen. Beteiligte Einrichtung: Labcorp, Greenfield, Indiana, USA. Hauptthemen laut MEDLINE: Thymoma, Thymus Neoplasms, Thymus Gland, Thymus Hyperplasia. Die Arbeit nennt 27 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Since the FDA’s approval in 2003, transgenic rasH2 (Tg.rasH2) mice have been used as alternative models to assess the carcinogenic potential of new drug candidates. While several articles documenting spontaneous non-neoplastic and neoplastic findings in Tg.rasH2 mice have been published, the incidence and morphologic criteria of proliferative thymic epithelial lesions have not been discussed in detail. Here we report the incidence and diagnostic morphologic criteria of non-neoplastic (epithelial hyperplasia) and neoplastic (benign and malignant thymoma) proliferative findings in the thymus. Incidences were derived through a review of pathology data from 3948 male and female control Tg.rasH2 mice from sixty-three 26-week carcinogenicity studies conducted at Labcorp, Madison, WI, between 2012 and 2024. Compared with published literature, an increased incidence of epithelial hyperplasia was noted in both sexes, with a higher incidence noted in females (7.4%) versus males (3.4%). Benign thymomas occurred at a higher-than-published incidence in both sexes, being more frequent in females (1.8% in females vs 0.7% in males), and our data also documented the first occurrence of malignant thymoma in this mouse strain, which was also more common in females (1% in females vs 0.7% in males). The epithelial features of selected proliferative findings were confirmed by immunohistochemistry using pan-cytokeratin.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ThymomaThymus NeoplasmsThymus GlandThymus HyperplasiaAnimalsMice, TransgenicFemaleMaleMiceCarcinogenicity TestsHyperplasia

Stichwörter der Autor:innen

benignepithelial hyperplasiaimmunohistochemistrymalignantrasH2 transgenic micethymomathymus

Autor:innen und Institutionen

  • Labcorp, Greenfield, Indiana, USA.
  • Labcorp, Madison, Wisconsin, USA.
  • Labcorp, Chantilly, Virginia, USA.

ORCID-Profile: Sasmita Mishra, Vimala Vemireddi, Marcia E Pereira Bacares, Molly H Boyle, Mark Mense, Alok K Sharma

Zitieren

APA

Mishra, S., Vemireddi, V., Pereira Bacares, M. E., Boyle, M. H., Mense, M., & Sharma, A. K. (2026). Thymic Epithelial Hyperplasia and Thymoma in Control rasH2 Transgenic Mice From 26-Week Carcinogenicity Assays. Toxicologic Pathology, 54(4), 297-306. https://doi.org/10.1177/01926233261429439

Vancouver

Mishra S, Vemireddi V, Pereira Bacares ME, Boyle MH, Mense M, Sharma AK. Thymic Epithelial Hyperplasia and Thymoma in Control rasH2 Transgenic Mice From 26-Week Carcinogenicity Assays. Toxicologic Pathology. 2026;54(4):297-306. doi:10.1177/01926233261429439

BibTeX
@article{Mishra2026,
  author = {Mishra, Sasmita and Vemireddi, Vimala and Pereira Bacares, Marcia E and Boyle, Molly H and Mense, Mark and Sharma, Alok K},
  title = {Thymic Epithelial Hyperplasia and Thymoma in Control rasH2 Transgenic Mice From 26-Week Carcinogenicity Assays},
  journal = {Toxicologic Pathology},
  year = {2026},
  volume = {54},
  number = {4},
  pages = {297--306},
  doi = {10.1177/01926233261429439}
}
Kostenlos starten →